The double opportunity in Chinese healthtech

24 February 2025

China’s healthcare sector is being transformed by demographics. The country has one of the fastest-growing ageing populations in the world: the percentage of people over 60 years old is projected to reach 28% by 2040,^[1] thanks to longer life expectancy and declining fertility rates.

Healthcare spending in China is expected to surge in tandem, to about USD28 trillion by 2030.^[2]

This rapid expansion is fuelling demand for innovative medical solutions, giving a fillip to China’s healthtech industry – not only to meet domestic needs but also to position itself as a major force in the global market. For investors, the sector presents compelling opportunities, especially given that they can use securities-backed financing to navigate the market.

The recent performance of some of China’s most innovative drug companies offers a glimpse of some of those opportunities. Since the stock market rally in the country in late September 2024, the Innovative Drugs Concept Index, tracked by Chinese data provider Wind, has outperformed the major CSI Healthcare Total Return Index and the CSI 300 by 10%.^[3] This trend signals investor confidence in the future of healthcare and biotechnology, buoyed by advancements in technology as well as supportive policies from the government.

One key technological advancement that can help the healthtech sector flourish is the adoption of artificial intelligence (AI), which can play a critical role in areas like drug discovery.^[4] Chinese AI platform DeepSeek took the world by storm in January when it unveiled a free AI assistant that it claims uses less data and operates at a fraction of the cost of existing services, giving existing platforms like ChatGPT a run for their money.

AI has similar potential to disrupt the healthcare sector. Since 2018, more than 100 pharmaceutical companies that leverage AI in their operations have been established in China, each with unique algorithms and focusing on medical imaging devices, diagnostics and drug discovery.^[5]

The first drugs fully generated by AI entered clinical trials with human patients in 2023 in China – and many pharma groups are now investing heavily in research and development given the long-term prospects of using AI for drug discovery.^[6] With China’s chronic and autoimmune drug market expected to be worth some USD 20 billion by 2030,^[7] the role of AI will likely be vast.

This matters to China because of its need for new drugs to combat ageing-related conditions, such as neurodegenerative, heart and pulmonary diseases.

Fuelling investments

Work is already underway. The Chinese government has long stepped in to fill funding gaps in the AI sector, supporting domestic companies with capital and aid, while there is an emerging crop of AI start-ups supported by Tsinghua University that are pushing the boundaries on innovation.^[8]

China also already leads the world in generative AI patents, having filed patents for 38,000 generative AI investments between 2014 and 2023, versus about 6,276 from the US.^[9]

While the size of and investment support for the US AI market dwarfs that of China, China’s AI industry is proving highly appealing to Middle Eastern funds, including sovereign wealth funds, that see the potential for a healthtech boom.

For example, the Qatar Investment Authority was a cornerstone investor in the November 2023 IPO of Chinese biotech company WuXi XDC,^[10] while in mid-2024, Bahrain-based investment firm Investcorp and sovereign wealth fund China Investment Corporation launched a USD1 billion platform to invest in high-growth companies in the Gulf and in China across industries including healthcare.^[11]

The sector is also attracting foreign investment, following recent moves by China to open its biotech industry to overseas enterprises.^[12]

Local Chinese technology companies, which are already familiar with and ingrained in the world of cloud computing and AI systems, are jumping on the bandwagon, too.

More than one in 10 of the start-up investments made by internet company Tencent in the last five years have been in healthcare – of which about 72% were in Mainland China and Hong Kong – while Alibaba Group and JD.com are also making inroads in the space.^[13]

These companies’ tech capabilities make them particularly suited to the healthtech and digital healthcare industries. For instance, at Alibaba Health Information Technology, digital healthcare is a core pillar of its business – something it is keen to bolster while exploring further use of AI large speech models across the healthcare and medical fields.^[14]

Capitalising on opportunities

As China’s healthcare industry gains traction, investors have a double opportunity: new companies are emerging as start-ups mature and grow, while healthtech is providing names in other sectors with a new aspect to their investment story. This also means investors are faced with a challenge: how to capitalise on these new opportunities while maintaining exposures to existing high-performing assets.

Enter securities-backed financing, which allows investors to unlock liquidity from their existing portfolio. It works particularly well in a sector like healthtech, where timing is critical for capturing fast-emerging opportunities. By leveraging their securities, investors can deploy capital into promising healthtech firms while holding onto their existing blue-chip positions.

Careful risk management is critical. Given the inherent volatility in a sector like healthtech, investors should keep a close eye on everything from market fluctuations and regulatory shifts to company-specific risks and valuations before going down the securities-backed financing route.

But the long-term trajectory of China healthtech investing is promising, as the combination of AI-fuelled innovation, government support and growing international investment creates a fertile ground for growth. Navigating this strategically, including by using securities-backed financing, can put investors in a strong position to benefit from the market’s potential.

[1] https://www.who.int/china/health-topics/ageing

[2] https://www.invesco.com/apac/en/institutional/insights/equity/china-healthcare-outlook-for-2025.html

[3] https://www.invesco.com/apac/en/institutional/insights/equity/china-healthcare-outlook-for-2025.html

[4] https://globalventuring.com/corporate/investment/tencent-china-healthcare-investment/

[5] https://www.chinadaily.com.cn/a/202403/18/WS65f7fb89a31082fc043bd3e3.html

[6] https://www.jpmorgan.com/insights/global-research/artificial-intelligence/ai-transforming-industries-china

[7] https://www.jpmorgan.com/insights/global-research/artificial-intelligence/ai-transforming-industries-china

[8] https://itif.org/publications/2024/08/26/how-innovative-is-china-in-ai/

[9] https://www.reuters.com/technology/artificial-intelligence/china-leading-generative-ai-patents-race-un-report-says-2024-07-03/

[10] https://www.bdapartners.com/wp-content/uploads/2024/04/2024-China-Healthcare-MA-Outlook_16Apr24.pdf

[11] https://www.al-monitor.com/originals/2024/04/bahrains-investcorp-chinas-cic-launch-1b-sino-gulf-investment-platform

[12] https://rouse.com/insights/news/2024/china-s-new-policies-on-foreign-investment-in-healthcare-and-biotechnology-catalyzing-innovation-and-strengthening-patent-protection

[13] https://globalventuring.com/corporate/investment/tencent-china-healthcare-investment/

[14] https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1113/2024111300821.pdf

Disclaimer

Past performance does not guarantee future returns, and individual returns are not guaranteed or warranted.

This Document is intended solely for accredited investors, sophisticated investors, professional investors, or otherwise qualified investors, as may be required by law or otherwise, and it is not intended for, and should not be used by, persons who do not meet the relevant requirements. The content provided herein is for informational purposes only and is general in nature and not targeted to any specific objective or financial need. The views and opinions expressed in this Document have been prepared by third parties and do not necessarily reflect the views and opinions of EquitiesFirst. EquitiesFirst has not independently examined or verified the information provided herein, and no representation is made that it is accurate or complete. Opinions and information herein are subject to change without notice. The content provided does not constitute an offer to sell (or solicitation of an offer to purchase) any securities, investments, or any financial products (“Offer”). Any such Offer shall only be made through a relevant offering or other documentation which sets forth its material terms and conditions. Nothing contained in this Document shall constitute a recommendation, solicitation, invitation, inducement, promotion, or offer for the purchase or sale of any investment product by Equities First Holdings, LLC or its subsidiaries (collectively, “EquitiesFirst”), nor shall this Document be construed in any way as investment, legal, or tax advice, or as a recommendation, reference, or endorsement by EquitiesFirst. You should seek independent financial advice prior to making an investment decision about a financial product.

This Document contains the intellectual property of EquitiesFirst in the United States and other countries, including, without limitation, their respective logos and other registered and unregistered trademarks and service marks. EquitiesFirst reserves all rights in and to their intellectual property contained in this Document. The Document should not be distributed, published, reproduced or otherwise made available in whole or in part by recipients to any other person and, in particular, should not be distributed to persons in any country where such distribution may lead to a breach of any legal or regulatory requirement.

EquitiesFirst make no representation or warranty with respect to this Document and expressly disclaim any implied warranty under law. You acknowledge that EquitiesFirst is not liable under any circumstances for any direct, indirect, special, consequential, incidental, or punitive damages whatsoever, including, without limitation, any lost profits or lost opportunity, even if EquitiesFirst has been advised of the possibility of such damages.

EquitiesFirst makes the following further statements that may be applicable in the stated jurisdiction:

The information contained on this Document is intended for persons located in Australia only and classified as a Wholesale Client only as defined in Section 761G of the Corporations Act 2001. The distribution of information to persons outside this criteria may be restricted by law and persons who come into possession of it should seek advice and observe any such restriction.

The material contained in this Document is for information purposes only and should not be construed as an offer or solicitation or recommendation to buy or sell financial products.

The information contained in this Document is intended to be general in nature and is not personal financial product advice. Any advice contained in the Document is general advice only and has been prepared without considering your objectives, financial situation or needs. Before acting on any information, you should consider the appropriateness of the information provided and the nature of the relevant financial product having regard to your objectives, financial situation and needs. You should seek independent financial advice and read the relevant disclosure statements or other offer documents prior to making an investment decision about a financial product.

Dubai: Equities First Holdings Hong Kong Ltd (DIFC Representative Office) at Gate Precinct Building 4, 6th Floor, Office 7, Dubai International Financial Centre (commercial license number CL7354) is regulated by the Dubai Financial Services Authority (“DFSA”) as a Representative Office (DFSA Firm Reference No.: F008752). All rights reserved.

The information contained in this document is intended to be general in nature, and, to the extent that it is perceived as advice, any advice contained in this document is general advice only and has been prepared without considering your objectives, financial situation, suitability of the financial products or your needs.

The material contained in this document is for information purposes only and should not be construed as financial advice, including an offer or solicitation or recommendation to buy or sell financial products. The information contained in this document is intended to be general in nature and any advice contained in this document is general advice only and has been prepared without considering your objectives, financial situation, suitability of the financial products or your needs. Before acting on any information, you should consider the appropriateness of the information provided and the nature of the relevant financial product having regard to your objectives, financial situation and needs. If you do not understand the contents of this document, you should consult an authorised financial adviser.

This document relates to a financial product which is not subject to any form of regulation or approval by the DFSA. The DFSA has no responsibility for reviewing or verifying any documents in connection with this financial product. Accordingly, the DFSA has not approved this document or any other associated documents nor taken any steps to verify the information set out in this document, and has no responsibility for it.

Hong Kong: Equities First Holdings Hong Kong Limited is licensed under the Money Lenders Ordinance (Money Lender’s Licence No. 1659/2024) and to carry on the business of dealing in securities (Type 1 licence) under the Securities and Futures Ordinance (“SFO”) (CE No. BFJ407). This Document has not been reviewed by the Hong Kong Securities and Futures Commission. It is not intended as an offer to sell securities or a solicitation to buy any product managed or provided by Equities First Holdings Hong Kong Limited and is only intended for persons who qualify as Professional Investors under the SFO. This document is not directed to individuals or organizations for whom such offers or invitations would be unlawful or prohibited.

Korea: The foregoing is intended solely for sophisticated investors, professional investors or otherwise qualified investors who have sufficient knowledge and experience in entering into securities financing transactions. It is not intended for, and should not be used by, persons who do not meet those criteria.

United Kingdom: Equities First (London) Limited is authorised and regulated in the UK by the Financial Conduct Authority (“FCA”). In the UK, this Document is only being distributed and made available to persons of the kind described in Article 19(5) (investment professionals) and Article 49(2) (high net worth companies, unincorporated associations etc.) of Part IV of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (‘’FPO’’) and any investment activity to which this presentation relates is only available to, and will only be engaged in with, such persons. Persons who do not have professional experience in matters relating to investment or who are not persons to whom Article 49 of the FPO applies should not rely on this document. This Document is only prepared for and available to persons who qualify as Professional Investors under the Markets in Financial Instruments Directive.